Reported Earlier, Telix Reports Q3 2026 Group Revenue Of $245M, Up 19% YoY, With Precision Medicine Revenue Up 30% YoY To $201M On Gozellix And Illuccix Demand

Loading news article.

Reported Earlier, Telix Reports Q3 2026 Group Revenue Of $245M, Up 19% YoY, With Precision Medicine Revenue Up 30% YoY To $201M On Gozellix And Illuccix Demand | WAPE

Reported Earlier, Telix Reports Q3 2026 Group Revenue Of $245M, Up 19% YoY, With Precision Medicine Revenue Up 30% YoY To $201M On Gozellix And Illuccix Demand

Article summary

Related companies

Comments —